Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort (original) (raw)

Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters

Suely Tuboi

AIDS, 2003

View PDFchevron_right

A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection

David Cohn

New England Journal of Medicine, 1994

View PDFchevron_right

Rapid initiation of antiretroviral therapy for people living with HIV

Alberto mateo urdiales

Cochrane Database of Systematic Reviews, 2018

View PDFchevron_right

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Dimitrios Paraskevis

Journal of the International AIDS Society

View PDFchevron_right

Prospective Randomized Trial of Emtricitabine versus Lamivudine Short‐Term Monotherapy in Human Immunodeficiency Virus–Infected Patients

Ian Sanne

The Journal of Infectious Diseases, 2003

View PDFchevron_right

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS

Asabo Samuel

Reviews, 2013

View PDFchevron_right

Efficacy of 1998 Vs 2006 first-line antiretroviral regimens for HIV infection: An ordinary clinics retrospective investigation

Giovanni Pellicanò

2012

View PDFchevron_right

Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903

Juan Berenguer Berenguer

Clinical Infectious Diseases, 2008

View PDFchevron_right

Predictors of short-term success of antiretroviral therapy in HIV infection

Dieter Häussinger

Journal of Antimicrobial Chemotherapy, 2006

View PDFchevron_right

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a …

Enric Pedrol

Clinical Infectious …, 2008

View PDFchevron_right

Mortality and progression to AIDS after starting highly active antiretroviral therapy

Peter Reiss

AIDS, 2003

View PDFchevron_right

HIV management in practice

Theresa Rossouw

Continuing Medical Education, 2011

View PDFchevron_right

of HIV-infected patients from the

Pompeyo Viciana

2015

View PDFchevron_right

Reomendaciones Recientes Para el Manejo de PACIENTES HIV

Karen Sanchez

View PDFchevron_right

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

Ruben Lopez

PLoS Medicine, 2012

View PDFchevron_right

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

Laine Pinto

Journal of the International AIDS Society, 2015

View PDFchevron_right

Treatment of AIDS and HIV- Related Conditions: 2000

Betty Dong

Journal of the American Board of Family Medicine, 2000

View PDFchevron_right

Use of Highly Active Antiretroviral Therapy in a Cohort of HIV-Seropositive Women

Lytt Gardner

American Journal of Public Health, 2002

View PDFchevron_right

Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean

Suely Tuboi

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2009

View PDFchevron_right

A Proof‐of‐Concept Study of Short‐Cycle Intermittent Antiretroviral Therapy with a Once‐Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection

April Powers

The Journal of Infectious Diseases, 2004

View PDFchevron_right

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting

Dolorès Vaira

AIDS, 2014

View PDFchevron_right

Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy

Catherine O'Connor

PLoS ONE, 2012

View PDFchevron_right

Short-Course Antiretroviral Therapy in Primary HIV Infection

Mauro Schechter

New England Journal of Medicine, 2013

View PDFchevron_right

Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz

Joseph Okopi

GERMS, 2015

View PDFchevron_right

Treatment of AIDS and HIV-Related Conditions-1999

Betty Dong

Journal of the American Board of Family Medicine, 1999

View PDFchevron_right

Drug-Resistant HIV Infection among Drug-Naive Patients in Israel

Dina Averbuch

Clinical Infectious Diseases, 2005

View PDFchevron_right

Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America

Valerie Stone

Clinical Infectious Diseases, 2004

View PDFchevron_right

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

Jean-michel Livrozet

Journal of the International AIDS Society, 2010

View PDFchevron_right